Grant of options and Directors Dealing

RNS Number : 6161I

C4X Discovery Holdings PLC

14 December 2020

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

Grant of options and Directors Dealing

14 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 600,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 200,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below.

Director	Position	Number of share options awarded	Option exercise price per share (pence)	Total number of options held
Dr Clive Dix	Chief Executive Officer	200,000	20	645,000
Dr Craig Fox	Chief Scientific officer	200,000	20	700,000
Brad Hoy	Chief Financial Officer	200,000	20	800,000

The options have an exercise price of 20 pence, being the average 5-day VWAP of the ordinary shares to the 11 December 2020.  The options can be exercised at any time between three and 10 years of them being granted.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name(s)	Dr Clive Dix
2	Reason for the notification
a)	Position/status	Chief Executive Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of o ptions over o rdinary s hares
c)	Price(s) and volume(s)	Price(s) Volume(s) 20 p 20 0,000
d)	Aggregated information
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Craig Fox
2	Reason for the notification
a)	Position/status	Chief Scientific Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of o ptions over o rdinary s hares
c)	Price(s) and volume(s)	Price(s) Volume(s) 20 p 20 0,000
d)	Aggregated information
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	London Stock Exchange - AIM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Brad Hoy
2	Reason for the notification
a)	Position/status	Chief Financial Officer, Director
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	C4X Discovery Holdings plc
b)	LEI	213800UHNL82E323O870
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan ISIN GB00BQQ2RV18
b)	Nature of the transaction	Grant of o ptions over o rdinary s hares
c)	Price(s) and volume(s)	Price(s) Volume(s) 20 p 20 0,000
d)	Aggregated information
e)	Date of the transaction	14 December 2020
f)	Place of the transaction	London Stock Exchange - AIM

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]

Notes to Editors:

About C4X Discovery

C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.

C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: www.c4xdiscovery.com

 

END

 

 

DSHUSABRROUUAAA